FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
What happened
FDA reviewed records Laboratorios Dr. Collado submitted after FDA's August 25, 2025 request for records under section 704(a)(4) of the FD&C Act, plus later correspondence. It found significant current good manufacturing practice (CGMP) violations for an over-the-counter drug product containing talc, including missing asbestos specifications and testing, inadequate contract-lab asbestos testing, and quality-unit oversight failures. No inspection was reported; FDA acted on the records review.
What FDA found
The company lacked adequate written specifications and laboratory tests for talc, including a test for the absence of asbestos.
21 CFR 211.160(b)The company did not show that its contract laboratory used an adequate method for asbestos testing; submitted electron microscope data at low magnification could not reliably identify asbestos fibers.
21 CFR 211.160(b)The company did not demonstrate that incoming talc was appropriately tested or that its test methods were validated for their intended use.
21 CFR 211.160(b)The quality unit (QU), the group responsible for quality oversight, approved talc for use without reviewing or approving asbestos test methods and specifications and without overseeing the contract laboratory.
21 CFR 211.22
What FDA wants
FDA tells the company to respond in writing within 15 working days with correction plans, and to provide talc retain testing results within 30 calendar days plus a risk assessment and actions for any lots that could contain asbestos.
Who should pay attention
- brands sourcing over-the-counter drugs from this facility
- companies using talc in over-the-counter drugs
- quality teams managing contract testing laboratories
This is a summary. Read the original letter on fda.gov.